Cardiovascular Event Reduction

Ez-PAVE directly compared LDL cholesterol targets below 55 and 70 mg/dL in adults with established atherosclerotic cardiovascular disease. Over three years, intensive targeting reduced the primary cardiovascular outcome from 9.7% to 6.6%, mainly through fewer heart attacks and revascularization procedures. The trial strengthens the case for lower LDL goals in secondary prevention while showing a broadly similar safety profile between treatment strategies in this population.